Research: Prevention and Control

Permanent URI for this collection

Research that investigated anticipated models of spread of COVID-19; measures that have been employed on the continent, including lockdowns and their efficacy; contextual methodologies of identifying potentially infectious asymptomatic subjects on the continent considering country testing capabilities; and innovations that can address the needs of healthcare workers and care facilities, given the global lack of sufficient personal protective equipment (PPEs) and ventilators that could be developed/scaled/produced on the continent.

Browse

Recent Submissions

Now showing 1 - 4 of 4
  • Item
    COVID ANIMATIONS: Bringing film to life (Presentation)
    (2023) Lugemwa, Abbas; Gibb, Tom
    Traditional journalists, politicians, elders, and opinion leaders dominated ‘information’ and communications about the pandemic. Scientists were either side-lined, or didn’t know how to communicate the right information they had, had no resources to do it or all the information there was, wasn’t reaching them in time. The ‘COVID ANIMATIONS: Bringing film to life’ project employed a collaborative approach to science engagement and journalism with the aim of bridging the gap between COVID-19 scientific evidence generated and public health messaging. Using science-based community engagement to fight COVID-19 through animations and film journalism. Themes: -Creating COVID-19 community awareness and response through film -Mitigating the negative impact of COVID-19 on; Maternal and child health and HIV/AIDS care services
  • Item
    COVID animations – Bringing Film to Life (Poster)
    (2023) Lugemwa, Abbas; Gibb, Tom; Kityo, Cissy; Ahebwa, Iqra; Ssempiri, Geofrey; Nakisekka, Mariam; Mugerwa, Henry
    At the pick of COVID 19 pandemic there was limited scientific information reaching the political and technical teams for timely and evidence-based information sharing with the general population. Restrictions aimed at slowing the spread of coronavirus along with disinformation, affected pandemic control measures and general health care delivery. It threatened to undermine public health targets and achievements built up over many years in areas such as Prevention of Mother to Child Transmission of HIV/AIDS, Tuberculosis, Childhood Vaccination and Maternal and Child Healthcare. We adopted a collaborative approach to confront this, building on existing relationships and previous collaborations between diverse disciplines and institutions. This involved researchers, community organisers, community leaders, frontline healthcare providers and health communicators and journalists. The aim was to provide core and relevant information to help communities to improve outcomes from the COVID 19 pandemic, including shielding the elderly and vulnerable and vaccination; to inform about the interaction between COVID and other conditions.
  • Item
    Experiences and Lessons from Structural Interventions Against COVID-19 in Addis Ababa, Ethiopia
    (2024-01-26) Engdawork, Kibur; Amdework, Ezana; Assefa, Samuel; Ayode, Desta; Tadele, Getnet
  • Item
    Comparative analysis of the antibody titers to different SARS-COV-2 vaccines  in vaccinated tertiary students in Botswana
    (2023) Maswabi, Bokang
    Rapidly evolving new variants of SARS-CoV-2, e.g., alpha, beta, delta and omicron, were associated with higher transmissibility and pathogenicity causing new waves of infections in most countries. During the Covid-19 pandemic Botswana like most countries in Africa initiated a rigorous vaccine program to protect its population. Due to the dynamics of vaccine availability Botswana engaged in a heterologous mix and match vaccine strategy which relied on using generally available vaccines while. The country prioritised vulnerable citizens. Hence subjects received various vaccines and in various regimen in both Homologous and heterologous combinations. In Botswana, the administered vaccines included inactivated virus-based vaccines Sinovac/CoronaVac, mRNA-based vaccines Pfizer-BioNTech and Moderna and lastly viral vector-based vaccines AstraZeneca and Janssen by Johnson & Johnson. These vaccines stimulate immune responses, including B-cell (humoral/antibody) activation with subsequent production of antibodies (IgM, IgG, IgA) [2,3,4]. Research work was done to analyse and quantify induced antibody titers (IgM and IgG) in vaccinated and non-vaccinated individuals during the Covid-19 pandemic. We also enrolled participants in a longitudinal cohort-based sero-epidemiological survey to quantify the proportion of subjects who were seropositive at various points during Covid-19 pandemic.